Close
Digital Health & Ai Innovation summit 2026
APE 2026

News

Tech-enabled clinical trial platform Castor secures $12 million to further COVID-19 research

Castor, a leading provider of clinical trial technology that automates the research process, announced that it has raised $12 million in funding. The round was...

Quest Diagnostics and Quest Diagnostics Foundation Launch Initiative to Reduce Health Disparities in Underserved Communities

Quest Diagnostics Incorporated, the world's leading provider of diagnostic information services, and the Quest Diagnostics Foundation, announced a wide-ranging initiative to address and reduce health...

Ehave Announces Plans to Accelerate the Monetization of its Proprietary Digital Health Platform

Ehave, Inc.,, a provider of digital therapeutics delivering evidence-based therapeutic interventions to healthcare patients, announced today it is accelerating plans to monetize its Ehave Dashboard....

Amedisys Expands Personal Care Network with BrightStar Care

Amedisys, Inc., America’s leading independent home health, hospice and personal care company, has signed a Care Coordination Agreement with BrightStar Care to add its agencies...

Massachusetts General Hospital researchers create bioluminescent tag to detect DNA break repair

A new bioluminescent reporter that tracks DNA double stranded break (DSB) repair in cells has been developed by researchers from Massachusetts General Hospital (MGH) and...

Penn Medicine health system gets $2.5M to study RPM’s effect on COVID-19 disparities

Penn Medicine’s COVID Watch team has received a $2.5 million grant from the Patient-Centered Outcomes Research Institute (PCORI) to study the program’s impact, particularly among...

LumiraDx gets FDA EUA status for point-of-care Covid-19 antigen test

LumiraDx has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its point-of-care Covid-19 antigen test. LumiraDx SARS-CoV-2 antigen test has...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »